Logo image of ATH

ATHENE HOLDING LTD-CLASS A (ATH) Stock Fundamental Analysis

NYSE:ATH - New York Stock Exchange, Inc. - Common Stock

83.33  -0.58 (-0.69%)

After market: 79.72 -3.61 (-4.33%)

Fundamental Rating

2

Overall ATH gets a fundamental rating of 2 out of 10. We evaluated ATH against 143 industry peers in the Insurance industry. Both the profitability and financial health of ATH have multiple concerns. ATH is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ATH had positive earnings in the past year.
ATH Yearly Net Income VS EBIT VS OCF VS FCFATH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 1B 2B 3B 4B

1.2 Ratios

Industry RankSector Rank
ROA 1.72%
ROE 18.92%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATH Yearly ROA, ROE, ROICATH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 5 10 15

1.3 Margins

ATH does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 13.83%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATH Yearly Profit, Operating, Gross MarginsATH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 5 10 15 20 25

1

2. Health

2.1 Basic Checks

ATH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATH Yearly Shares OutstandingATH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M
ATH Yearly Total Debt VS Total AssetsATH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 50B 100B 150B 200B

2.2 Solvency

A Debt/Equity ratio of 0.12 indicates that ATH is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
ATH Yearly LT Debt VS Equity VS FCFATH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 5B 10B 15B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 156.13% over the past year.
The Earnings Per Share has been growing by 28.79% on average over the past years. This is a very strong growth
Looking at the last year, ATH shows a very strong growth in Revenue. The Revenue has grown by 185.80%.
Measured over the past years, ATH shows a very strong growth in Revenue. The Revenue has been growing by 39.53% on average per year.
EPS 1Y (TTM)156.13%
EPS 3Y38.1%
EPS 5Y28.79%
EPS Q2Q%78.43%
Revenue 1Y (TTM)185.8%
Revenue growth 3Y19.44%
Revenue growth 5Y39.53%
Sales Q2Q%174.43%

3.2 Future

The Earnings Per Share is expected to grow by 5.01% on average over the next years.
Based on estimates for the next years, ATH will show a small growth in Revenue. The Revenue will grow by 7.89% on average per year.
EPS Next Y127.39%
EPS Next 2Y22.49%
EPS Next 3Y18.34%
EPS Next 5Y5.01%
Revenue Next Year33.16%
Revenue Next 2Y14.05%
Revenue Next 3Y11.88%
Revenue Next 5Y7.89%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ATH Yearly Revenue VS EstimatesATH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B
ATH Yearly EPS VS EstimatesATH Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 5.78, the valuation of ATH can be described as very cheap.
When comparing the Price/Earnings ratio of ATH to the average of the S&P500 Index (28.04), we can say ATH is valued rather cheaply.
The Price/Forward Earnings ratio is 8.86, which indicates a very decent valuation of ATH.
ATH is valuated cheaply when we compare the Price/Forward Earnings ratio to 37.64, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 5.78
Fwd PE 8.86
ATH Price Earnings VS Forward Price EarningsATH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.07
ATH Per share dataATH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ATH's earnings are expected to grow with 18.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.05
PEG (5Y)0.2
EPS Next 2Y22.49%
EPS Next 3Y18.34%

0

5. Dividend

5.1 Amount

No dividends for ATH!.
Industry RankSector Rank
Dividend Yield N/A

ATHENE HOLDING LTD-CLASS A

NYSE:ATH (12/13/2021, 8:19:38 PM)

After market: 79.72 -3.61 (-4.33%)

83.33

-0.58 (-0.69%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupInsurance
GICS IndustryInsurance
Earnings (Last)11-03 2021-11-03
Earnings (Next)N/A N/A
Inst Owners2.22%
Inst Owner Change0%
Ins Owners0.22%
Ins Owner Change-12.14%
Market Cap16.01B
Analysts67.5
Price Target85.57 (2.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP3.47%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 5.78
Fwd PE 8.86
P/S 0.57
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB N/A
EV/EBITDA 2.07
EPS(TTM)14.42
EY17.3%
EPS(NY)9.41
Fwd EY11.29%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS145.22
BVpS106.14
TBVpSN/A
PEG (NY)0.05
PEG (5Y)0.2
Profitability
Industry RankSector Rank
ROA 1.72%
ROE 18.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 13.83%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)156.13%
EPS 3Y38.1%
EPS 5Y28.79%
EPS Q2Q%78.43%
EPS Next Y127.39%
EPS Next 2Y22.49%
EPS Next 3Y18.34%
EPS Next 5Y5.01%
Revenue 1Y (TTM)185.8%
Revenue growth 3Y19.44%
Revenue growth 5Y39.53%
Sales Q2Q%174.43%
Revenue Next Year33.16%
Revenue Next 2Y14.05%
Revenue Next 3Y11.88%
Revenue Next 5Y7.89%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A